法律意见书 北京海润天睿律师事务所 关于梅花生物科技集团股份有限公司 2024 年年度股东大会的法律意见书 致：梅花生物科技集团股份有限公司 北京海润天睿律师事务所接受梅花生物科技集团股份有限公司（以下简称公 司）的委托，对公司于 2025 年 4 月 15 日召开的 2024 年年度股东大会（以下简 称"本次股东大会"或"会议"）进行见证，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"） 和《梅花生物科技集团股份有限公司章程》（以下简称"《公司章程》"）的规 定，按照律师行业公认的业务标准、道德规范和勤勉尽责精神，对公司本次股东 大会的召集、召开程序、出席会议人员的资格、表决程序及结果等有关事宜发表 法律意见。 一、本次股东大会的召集、召开程序 本次股东大会的召集人系公司董事会。 2025 年 3 月 17 日，公司第十届董事会第十八次会议作出召开 2024 年年度 股东大会的决议，董事会以公告形式向全体股东发出《梅花生物科技集团股份有 限公司关于召开 2024 年年度股东大会的通知》（以下简称"会议通知"），该会议 通知刊登于上海证券交易所网站 ...

证券代码：600873 证券简称：梅花生物 公告编号：2025-032 梅花生物科技集团股份有限公司 2024 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025 年 4 月 15 日 (二)股东大会召开的地点：河北省廊坊市经济技术开发区华祥路 66 号公司 会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 657 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 1,433,623,232 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 50.2533 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 会议由董事长王爱军女士主持，会议的召开程序及表决方式符合《公司法》 及《公司章程》的有关规定。 (五)公司董事、监事和董事会秘书的出席情况 ...

Group 1 - The Chinese government has announced an increase in tariffs on all imported goods from the United States, raising the tariff rate from 34% to 84%, which significantly impacts soybean imports [1] - The total tariff on U.S. soybeans has increased to 94%, which is expected to shift global soybean demand towards Brazil, benefiting domestic soybean meal prices [1] - In 2024, China's soybean imports are projected to be approximately 105 million tons, with 71% sourced from Brazil and 21% from the U.S., indicating a strong reliance on Brazilian soybeans due to seasonal factors [1] Group 2 - The rise in soybean meal prices is expected to positively impact company performance, as the correlation between soybean and corn prices may lead to an increase in corn prices, benefiting companies reliant on corn as a core cost item [2] - The company has announced a profit distribution plan for 2024, with a total cash dividend and buyback amounting to 2.27 billion yuan, representing 82.84% of the net profit attributable to shareholders, resulting in a dividend yield of 7.3% [2] - Profit forecasts for 2025-2027 have been adjusted to 3.04 billion, 3.34 billion, and 3.61 billion yuan, reflecting year-on-year growth of 10.9%, 10.0%, and 7.9%, with corresponding PE ratios of 10, 9, and 9 times [2]

Group 1 - The company will hold the 2024 annual general meeting on April 15, 2025, at 14:00, using a combination of on-site and online voting methods [1] - To enhance service for small and medium investors, the company will utilize the Shanghai Stock Exchange Information Co., Ltd. to provide a shareholder meeting reminder service [2] - Investors will receive proactive notifications about the meeting and voting proposals via smart SMS, allowing them to vote directly according to the provided instructions [2]

特此公告。 梅花生物科技集团股份有限公司（以下简称"公司"）于 2025 年 3 月 18 日 披露了《梅花生物关于召开2024年年度股东大会的通知》（公告编号：2025-025）， 公司拟于 2025 年 4 月 15 日 14:00 召开 2024 年年度股东大会，本次会议采用现 场投票和网络投票相结合的表决方式。 为更好地服务广大中小投资者，确保有投票意愿的中小投资者能够及时参会、 及时投票。公司拟使用上证所信息网络有限公司（以下简称"上证信息"）提供 的股东大会提醒服务，委托上证信息通过智能短信等形式，根据股权登记日的股 东名册主动提醒股东参会投票，向每一位投资者主动推送股东会参会邀请、议案 情况等信息。投资者在收到智能短信后，可根据使用手册（下载链接： https://vote.sseinfo.com/i/yjt_help.pdf）的提示步骤直接投票，如遇拥堵等情况，仍 可通过原有的交易系统投票平台和互联网投票平台进行投票。 若广大投资者对本次服务有任何意见或建议，可通过邮件、投资者热线等方 式向公司反馈，感谢广大投资者对公司的关注与支持！ 证券代码：600873 证券简称：梅花生物 公告编号：20 ...

ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) REPORT MEIHUA HOLDINGS GROUP CO., LTD. CONTENTS Introduction | About | This Report | | 01 | | --- | --- | --- | --- | | Message | from | Chairman | 05 | | About | Meihua | Group | 07 | Appendix | ESG data | sheets | | 103 | | --- | --- | --- | --- | | Benchmark | Index | Table | 114 | 01 ESG Governance | Sustainable development | | strategy | 15 | | --- | --- | --- | --- | | ESG | statement of the Board | | 19 | | | | | | | | ESG compliance governance | | 19 | | | ...

梅花生物科技集团股份有限公司 2024 年年度股东大会 会议资料 二○二五年四月 | | | | 2024 年年度股东大会会议须知 1 | | --- | | 2024 年年度股东大会会议议程 3 | | 议案一、关于 2024 年度董事会工作报告的议案 4 | | 议案二、关于 2024 年度监事会工作报告的议案 15 | | 议案三、关于 2024 年年度报告及其摘要的议案 16 | | 议案四、关于 2024 年度财务决算报告的议案 17 | | 议案五、关于 2025 年度预算方案的议案 18 | | 议案六、关于 2024 年度利润分配方案（预案）的议案 19 | | 议案七、关于预计 2025 年向全资子公司提供担保的议案 19 | | 议案八、关于使用闲置自有资金购买理财产品的议案 19 | | 议案九、关于开展金融衍生品交易业务的议案 20 | | 议案十、关于提请股东大会授权董事会决定 2025 年中期利润分配方案的议案 20 | | 议案十一、关于公司 2025 年重大投资计划的议案 21 | | 议案十二、关于 2024 年度董事、监事及高级管理人员绩效考核及薪酬兑现方案的议案 21 | ...

Group 1 - The core viewpoint of the report indicates steady revenue growth in the main business of the company, with a focus on flexible sensors to create a second growth curve [4][5][6] - The company achieved a revenue of 2.54 billion yuan in 2024, a year-on-year increase of 19.23%, and a net profit of 139 million yuan, up 98.42% year-on-year [4][5] - The company is transitioning from a single coating material provider to an integrated solution provider, enhancing revenue across various business segments [5][6] Group 2 - The report highlights that Lululemon's North American market growth is weak, with a revenue of 3.6 billion USD in FY2024Q4, a year-on-year increase of 13% [9][10] - The company expects a low to mid-single-digit revenue growth in North America for FY2025, with challenges from economic concerns affecting consumer traffic [11][12] - In contrast, the Chinese market showed strong growth, with a revenue increase of 48% year-on-year, indicating a robust performance in that region [11][12] Group 3 - The report on Tongyi Zhong indicates that the company achieved a revenue of 649 million yuan in 2024, a year-on-year increase of 1.4%, but net profit decreased by 15.2% [15][16] - The company reported a significant increase in production and sales volumes, with historical highs in major product categories [17][18] - The company is expanding into the aramid fiber sector, aiming to create dual growth drivers [15][21] Group 4 - Xiamen International Trade's report emphasizes its focus on supply chain management, with a strategy to navigate through commodity cycles [28][29] - The company has divested from real estate and financial services to concentrate on its core supply chain business, which includes metals, energy, and agriculture [29][30] - The report projects revenue for 2024 to 2026 at 389.05 billion yuan, 404.61 billion yuan, and 418.84 billion yuan, respectively, with a focus on maintaining a high dividend yield [32] Group 5 - The report on Bawang Tea indicates that it leads the high-end tea beverage market with 6,440 stores, achieving a GMV of 10.8 billion yuan in 2023 [33][34] - The company is benefiting from a growing market for high-end tea beverages, with a projected market size increase from 4.748 trillion yuan in 2019 to 8.189 trillion yuan in 2024 [34][35] - Bawang Tea's strategy focuses on a limited number of new products while optimizing supply chain efficiency, resulting in a gross margin of 51.5% [35] Group 6 - Aikodi's report shows a revenue of 6.746 billion yuan in 2024, a year-on-year increase of 13.24%, with a net profit of 940 million yuan [36][37] - The company is expanding its global footprint with new production bases in Malaysia and Mexico, enhancing its supply chain stability [39][40] - The report anticipates continued revenue growth driven by new product lines and market expansion, projecting revenues of 7.9 billion yuan in 2025 [40] Group 7 - Longxing Technology's report indicates a revenue of 4.355 billion yuan in 2024, with a net profit increase of 28.7% [41][42] - The company is expanding its production capacity with new projects and acquisitions, aiming to increase its market share in the carbon black industry [46] - The report highlights a significant improvement in gross margin, reaching 13.01% in Q4 2024, driven by operational efficiencies [45][46]

重要内容提示： 一、回购股份的基本情况 证券代码：600873 证券简称：梅花生物 公告编号：2025-030 梅花生物科技集团股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购方案首次披露日 | 2024/9/24 | | --- | --- | | 回购方案实施期限 | 待股东大会审议通过后 12 个月 | | 预计回购金额 | 30,000 万元~50,000 万元 | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 3,570.84 万股 | | 累计已回购股数占总股本比例 | 1.25% | | 累计已回购金额 | 35,202.44 万元 | | 实际回购价格区间 | 9.10 元/股~10.68 元/股 | 2025 年 3 月，公司通过集中竞价交易方式回购股份 151.93 万股，占公司目前 股本总数(2,852,788,750 ...

Investment Rating - The report maintains an "Outperform" rating for the company [2][9][10] Core Views - The company's Q4 2024 performance met expectations, with improvements anticipated in the amino acid sector and overall market conditions [1][9] - The company is expanding its product matrix through a cross-border acquisition, which is expected to enhance its overseas strategic layout [9][10] - The company has experienced a significant recovery in amino acid profitability, with Q4 2024 performance showing a notable increase in operational metrics [9][10] Financial Data and Profit Forecast - Total revenue for 2023 is projected at 27,761 million, with a decline to 25,069 million in 2024, followed by a recovery to 28,129 million in 2025, and further growth expected in subsequent years [8][10] - The net profit attributable to the parent company is forecasted to decrease from 3,181 million in 2023 to 2,740 million in 2024, before rebounding to 3,063 million in 2025 [8][10] - The gross profit margin is expected to stabilize around 19.5% in 2025, with a return on equity (ROE) projected at 19.6% [8][10] Market Data - As of March 19, 2025, the closing price of the company's stock is 10.41 yuan, with a market capitalization of 29,698 million yuan [2][9] - The company has a price-to-book ratio of 2.0 and a dividend yield of 5.72% based on the most recent dividend announcements [2][9]